{"url_path":"/sec/hepa/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1583771/0001493152-26-029085-index.html","accession_number":"0001493152-26-029085","cik":"0001583771","ticker":"HEPA","issuer_name":"Hepion Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583771/0001493152-26-029085-index.html","primary_entity_key":"0001583771","primary_entity_name":"Hepion Pharmaceuticals, Inc."},"word_count":285,"has_tables":true,"body_markdown":"**Item\n5.07. Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn\nJune 17, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the **“**Meeting”).\n\n \n\nAs\nof April 28, 2026, the record date for the Meeting, there were 29,119,476 shares of our common\nstock outstanding (including 85,581 shares of common stock issuable upon conversion of the Series A Preferred Stock).\n\n \n\nAt\nthe Meeting, the stockholders voted on the following three proposals and cast their votes as follows:\n\n \n\n1.\nTo elect the five (5) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of\nstockholders and until their respective successors have been duly elected and qualified consisting of Gary Stetz, Vincent LoPriore, Michael\nPurcell, Sireesh Appajosyula and Chase LoPriore.\n\n \n\nName \nVotes For \nWithhold \nBroker Non-Vote\n\nGary Stetz \n13,498,755 \n153,947 \n4,816,704\n\nVincent LoPriore \n13,492,507 \n160,195 \n4,816,704\n\nMichael Purcell \n13,186,912 \n465,790 \n4,816,704\n\nSireesh Appajosyula \n13,503,469 \n149,233 \n4,816,704\n\nChase LoPriore \n13,492,110 \n160,592 \n4,816,704\n\n \n\n2.\nTo ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December\n31, 2026.\n\n \n\nVotes For \nVotes Against \nVotes Abstained \nBroker Non-Vote\n\n18,128,998 \n116,985 \n223,423 \n0\n\n \n\n3.\nTo approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder\nto 8,000,000 from 200,000.\n\n \n\nVotes For \nVotes Against \nVotes Abstained \nBroker Non-Vote\n\n13,442,072 \n208,879 \n1,751 \n4,816,704\n\n \n\n-2-\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJune 17, 2026\n**Hepion\nPharmaceuticals, Inc.**\n\n \n \n \n\n \nBy:\n*/s/\nGary Stetz*\n\n \n \nGary\nStetz\n\n \n \nInterim\nChief Executive Officer\n\n \n\n-3-"}